SILMITASERTIB SODIUM

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H11ClN3O2.Na
Molecular Weight	371.752
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].[O-]C(=O)C1=CC2=C(C=C1)C3=CN=CC=C3C(NC4=CC=CC(Cl)=C4)=N2

InChI

InChIKey=ODDAAPQSODILSN-UHFFFAOYSA-M

InChI=1S/C19H12ClN3O2.Na/c20-12-2-1-3-13(9-12)22-18-15-6-7-21-10-16(15)14-5-4-11(19(24)25)8-17(14)23-18;/h1-10H,(H,22,23)(H,24,25);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula	C19H11ClN3O2
Molecular Weight	348.763
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Na
Molecular Weight	22.98976928
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://adisinsight.springer.com/drugs/800029427
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21159648

Silmitasertib (CX-4945) is a potent and selective orally bioavailable small molecule inhibitor of Casein kinase II (CK2). The antiproliferative activity of CX-4945 against cancer cells correlated with expression levels of the CK2α catalytic subunit. CX-4945 caused cell-cycle arrest and selectively induced apoptosis in cancer cells relative to normal cells. When administered orally in murine xenograft models, CX-4945 was well tolerated and demonstrated robust antitumor activity. Senhwa Biosciences is developing silmitasertib for the treatment of cholangiocarcinoma, other solid tumours, Castleman's disease (giant lymph node hyperplasia) and multiple myeloma. The compound was originally developed by Cylene Pharmaceuticals. Phase Ib/II development is underway in the US and South Korea for the treatment of cholangiocarcinoma, and development in the remaining indications is at the phase I stage. As at July 2016, no recent reports of development had been identified for phase-I development in Giant-lymph-node-hyperplasia in USA (PO, Capsule), phase-I development in Multiple-myeloma in USA (PO, Capsule), phase-I development in Solid-tumours (Late-stage disease) in USA (PO, Capsule).

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Casein kinase II alpha 3 Target ID: CHEMBL3629 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21159648	Inhibitor 8504		1.0 nM [IC50]
Casein kinase II alpha (prime) 2 Target ID: CHEMBL4070 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21159648	Inhibitor 8504		1.0 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Cholangiocarcinoma 18 Sources: http://adisinsight.springer.com/drugs/800029427	Primary	Phase II 1147	Unknown Approved Use Unknown
Multiple myeloma 159 Sources: http://adisinsight.springer.com/drugs/800029427	Primary	Phase I 438	Unknown Approved Use Unknown
Castleman's disease (giant lymph node hyperplasia) 2 Sources: http://adisinsight.springer.com/drugs/800029427	Primary	Phase I 438	Unknown Approved Use Unknown
Solid tumors 147 Sources: http://adisinsight.springer.com/drugs/800029427	Primary	Phase I 438	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
14.8 μg/mL EXPERIMENT http://www.imedpub.com/articles/phase-i-study-of-cigb300-administeredintravenously-in-patients-with-relapsedrefractory-solid-tumors.pdf	1.6 mg/kg single, intravenous dose: 1.6 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		SILMITASERTIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
11.4 μg × h/mL EXPERIMENT http://www.imedpub.com/articles/phase-i-study-of-cigb300-administeredintravenously-in-patients-with-relapsedrefractory-solid-tumors.pdf	1.6 mg/kg single, intravenous dose: 1.6 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		SILMITASERTIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
0.75 h EXPERIMENT http://www.imedpub.com/articles/phase-i-study-of-cigb300-administeredintravenously-in-patients-with-relapsedrefractory-solid-tumors.pdf	1.6 mg/kg single, intravenous dose: 1.6 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		SILMITASERTIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY100445	https://www.001chemical.com/chem/search?q=DY100445
1PlusChem LLC	1P0003T7	https://www.1pchem.com/search?query=1P0003T7
A2B Chem	AA04139	http://a2bchem.com/prod/AA04139
AbovChem LLC	HY-50855B	http://www.abovchem.com/pc/en/product_list.aspx?wd=HY-50855B
AChemBlock	10308	http://www.achemblock.com/catalogsearch/result/?q=10308
Achemo Scientific Limited	AC-34982	http://www.achemo.com/search/?Keyword=AC-34982
AK Scientific	SYN1109	https://aksci.com/item_detail.php?cat=SYN1109
AK Scientific	X7439	https://aksci.com/item_detail.php?cat=X7439
Ambeed	A103748	http://www.ambeed.com/search/Search.html?keyword=A103748
AOBIOUS INC	AOB2757	http://aobious.com/aobious/search?search_query=AOB2757
ApexBio Technology	A8330	https://www.apexbt.com/catalogsearch/result/?q=A8330
AstaTech	27746	http://astatechinc.com/CPSResult.php?CRNO=27746
Axon MedChem	1965	https://www.axonmedchem.com/product/1965
BioSynth	W-204393	https://www.biosynth.com/en/products/life-science/other-biochemicals/products/W-204393
BLD Pharm	BD630105	http://www.bldpharm.com/search/Search.html?keyword=BD630105
BOC Sciences	1009820-21-6	http://www.bocsci.com/description.asp?cas=1009820-21-6
Capot Chemical	22588	https://www.capotchem.com/search.do?q=22588
Cayman Chemical	16779	http://www.caymanchem.com/app/template/Product.vm/catalog/16779
ChemShuttle	102629	https://www.chemshuttle.com/catalogsearch/result/?q=102629
ChemShuttle	149122	https://www.chemshuttle.com/catalogsearch/result/?q=149122
Combi-Blocks	QB-3166	http://www.combi-blocks.com/cgi-bin/find.cgi?QB-3166
Debye Scientific	DB-016103	https://www.debyesci.com/index.php?id=product&ext[cno]=DB-016103
eMolecules	222573102	https://orderbb.emolecules.com/search/#?query=222573102
eMolecules	36370225	https://orderbb.emolecules.com/search/#?query=36370225
eMolecules	44818048	https://orderbb.emolecules.com/search/#?query=44818048
eMolecules	50550726	https://orderbb.emolecules.com/search/#?query=50550726
eNovation Chemicals	D372337	https://www.enovationchem.com/Products.asp?SEARCHTEXT=D372337&searchbtn.x=0&searchbtn.y=0
Excenen	EX-A070	http://www.excenen.com/searchresultlist.php?id=EX-A070
Fluorochem	213590	http://www.fluorochem.co.uk/Products/Product?code=213590
Hairui	HR106660	http://www.hairuichem.com/en/product/search.do?q=HR106660
KeyOrganics	AS-16253	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-16253
KeyOrganics	AS-16970	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-16970
Lab Network	LN00189045	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00189045
Lab Network	LN01342448	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01342448
Matrix Scientific	90615	http://www.matrixscientific.com/090615.html
mcule	MCULE-1514086393	https://mcule.com/MCULE-1514086393/
mcule	MCULE-6228704742	https://mcule.com/MCULE-6228704742/
MedChem Express	HY-50855	https://www.medchemexpress.com/search.html?q=HY-50855&ft=&fa=&fp=
Molcore	MC100445	http://www.molcore.com/CatMC100445.html
Molnova	M10065	https://www.molnova.com/en/serch-list.html?keywords=M10065
Molnova	M11234	https://www.molnova.com/en/serch-list.html?keywords=M11234
MolPort	MolPort-023-278-941	https://www.molport.com/shop/molecule-link/MolPort-023-278-941
MolPort	MolPort-042-665-789	https://www.molport.com/shop/molecule-link/MolPort-042-665-789
MolPort	MolPort-044-181-459	https://www.molport.com/shop/molecule-link/MolPort-044-181-459
MuseChem	I000112	https://www.musechem.com/product/I000112.html
PI Chemicals	PI-38267	http://www.pipharm.com/catalog_products/PI-38267.html
Ryan Scientific	Purvalanol_A	https://ryansci.com/products?q=Purvalanol_A&list_q=&search_type=exact
Selleck Chemicals	S2248	http://www.selleckchem.com/search.html?searchDTO.searchParam=S2248
ShangHai Biochempartner	BCP000343	http://www.biochempartner.com/search_BCP000343
ShangHai Biochempartner	BCP02399	http://www.biochempartner.com/search_BCP02399
Synthonix	SL100124	http://www.synthon-lab.com/search.php?cas_or_id=SL100124&cas_id_field=1
TargetMol	T2259	https://www.targetmol.com/search?keyword=T2259
Wonderchem	WD029KF	http://www.wonder-chem.com/search.html?text=WD029KF

PubMed

Title	Date	PubMed
Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma.	2013-12-01	24036851
Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer.	2011-01-27	21174434
CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.	2010-12-15	21159648

Patents

Sample Use Guides

In Vivo Use Guide

Interim results of a phase I trial showed that silmitasertib was well-tolerated in patients with solid tumours. Thirteen such patients (3-4 patients per cohort, from four separate dose cohorts) received oral, twice-daily doses of silmitasertib for 21 consecutive days of a 4-week cycle. The trial design provided for administration of silmitasertib in successive dose cohorts at 90mg, 160mg, 300mg, 460mg, 700mg and 1000mg per dose. No adverse events of grade ≥3 were reported. No dose-limiting toxicities had been observed and the maximum tolerated dose was yet to be defined.

Route of Administration: Oral

In Vitro Use Guide

Silmitasertib (CX-4945) exerts antiproliferative activity of in a panel of breast cancer cell lines with EC50 1.71-20.01 uM

Substance Class	Chemical Created by `admin` on `Mon Mar 31 19:34:04 GMT 2025` Edited by `admin` on `Mon Mar 31 19:34:04 GMT 2025`
Record UNII	N1E607PU86
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SILMITASERTIB SODIUM

Common Name

English

CX-4945 SODIUM

Preferred Name

English

CX4945 SODIUM

Code

English

5-((3-CHLOROPHENYL)AMINO)-BENZO(C)-2,6-NAPHTHYRIDINE-8-CARBOXYLIC ACID SODIUM SALT

Common Name

English

BENZO(C)-2,6-NAPHTHYRIDINE-8-CARBOXYLIC ACID, 5-((3-CHLOROPHENYL)AMINO)-, SODIUM SALT (1:1)

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1404